NGeneBio, a precision diagnosis platform based on next-generation sequencing (NGS), has signed a business agreement with Korea Agilent Technologies, a global medical analysis equipment company, to expand the NGS precision diagnosis market at home and abroad. 

NGS-based cancer precision diagnosis which examines many genes at once, is a key technology of precision medicine that can improve the prognosis of treatment by prescribing the optimal target treatment for each patient. However, the complexity of the experiment and the difficulty of analysing the genomic data are considered as the biggest hurdles in implementing the test in the clinical field.

South Korea-based NGeneBio, which has NGS precision diagnosis panel and analysis software, plans to overcome the complexity of NGS experiments and expand the NGS precision diagnosis market in earnest by creating synergy with automated equipment through a business agreement with Korea Agilent Technologies.

NGeneAnalySys, NGeneBio 's analysis software, has been recognised as a solution that automatically analyses vast amounts of genomic data and provides result reports, and is being used in about 20 high-end general hospitals in Korea.

Agilent's Magnis NGS Prep System is an automated device that can easily and quickly perform complex NGS examinations in clinical settings. The main business model of this business agreement is to apply ONCOaccuPanel, a solid cancer precision diagnosis product of NGeneBio, to Magnis automation equipment and sell it as a package.